16 Big Dividends We’re Avoiding Like Right Now

Our Archive

Search completed

16 Big Dividends We’re Avoiding Like Right Now

Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and downside!), as well as these funds’ 8%+ dividend payouts.

I was reminded of this recently by a story that’s unfolding in the UK, where two asset-management firms are struggling a bit to hire CEOs. One is Scotland-based abrdn plc (SLFPF), whose shares have risen just 2.6% annually in the US on average over the last decade.

Compare that to a roughly 10% average year-to-date return enjoyed by the other major asset managers abrdn is competing with, and you get a good idea of what’s happening here: abrdn isn’t doing well enough to attract the best talent.… Read more

Read More

The “Biden Biotech Boom” Will Send This Bargain 6.8% Dividend Soaring

Some major—and almost totally ignored—news from Washington, D.C., is about to upend the biotech world, turning America into “the world’s pharmacy” in short order—and giving us a chance to buy a solid 6.8% dividend for just 91 cents on the dollar.

That might sound hard to believe for woebegone biotechs, which have fallen further than the S&P 500 this year, going by the performance of the benchmark iShares Biotechnology ETF (IBB). That’s despite the sector’s importance during the pandemic—and despite the fact that some 10,000 Americans turn 65 every day, sharply increasing demand for pharmaceuticals as the senior cohort grows.

Biotech Catches a Cold

The problem is that despite these tailwinds, biotech is weighed down by the same problems that are dragging on the rest of the economy: lower R&D funding as interest rates rise, and supply-chain issues that are hurting productivity.… Read more

Read More

4 “Double Discounted” CEFs Yielding Up to 9.1% (Paid Monthly)

There’s nothing we closed-end fund investors love more than finding a smartly run fund in an unfairly beaten-down sector. This hands us a nice discount (of course!), plus a much bigger dividend, because yields and prices move in opposite directions.

In fact, with CEFs, we’re actually getting a “double discount”: one from the depressed sector and one from the CEF’s discount to net asset value (NAV, or the value of the stocks in its portfolio). This indicator only exists with CEFs, and we’ll cover 4 with particularly attractive discounts to NAV in a second.

Plus, CEFs already boast yields that triple (or more) those of regular stocks, so deep-discounted CEFs give you an income stream that’s bigger still.… Read more

Read More

3 Ways to Cash in on the Coming Healthcare Boom (With Huge 6%+ Dividends)

Most investors are ignoring a clear shot at 7%+ dividends double-digit price gains—year in and year out—in a sector everyone should be talking about, but isn’t.

That would be healthcare, which is riding a rocket of rising spending: according to the latest numbers from the Centers for Medicare & Medicaid Services, US health expenditures will soar 5.4% annually, on average, every year until 2028. (We’ll dive into three funds paying huge dividends up to 8.3% and poised to cash in on this wave in a moment.)

The thing about that 5.4% yearly increase is that it’s much bigger than projected US GDP growth of 4%.… Read more

Read More

2 “Workhorse” Monthly Dividend Payers Yielding up to 6% (With Upside)

Let’s jump on the market’s September slide and grab ourselves a sweet “double discount” on 358 totally ignored income plays—and some sweet 6%+ dividends, too. And our new income stream will pay us monthly!

Going Where Other Dividend Investors Don’t

Our route to this big monthly payout does an end run around the misers of the S&P 500. Even though the market dove 3.5% in September, that was only enough to drive yields on the big-name stocks up by—wait for it—0.07%.

In other words, if you dropped a million bucks into an ETF like the SPDR S&P 500 ETF Trust (SPY) in early September, you’d be generating $12,300 in yearly dividends.… Read more

Read More

3 Huge Monthly Dividends Set to Soar (One Yields an Incredible 7.6%)

When it comes right down to it, we dividend investors really only need three things:

  • Bargain stocks with …
  • High current yields and ideally …
  • Monthly payouts—so we can line up our income with our bills and reinvest our dividend cash without having to wait for three long months.

I know—this list is cute, but it sounds wildly out of step with the times.

After all, the COVID rally has sliced the typical S&P 500 stock’s yield to an unlivable 1.4%. And bargain valuations? Ha! Stocks trade at a helium-powered 37-times their last 12 months of earnings right now.

And we all know that to get monthly payouts, we must look beyond the popular stocks to lesser-known plays like real estate investment trusts (REITs) and closed-end funds (CEFs).… Read more

Read More

It’s Never Been Easier to Retire on Dividends (Can Be Done on $600K)

Let me start with a special shout out to our dedicated readers at Barron’s. Here at Contrarian Outlook, we’ve been drawing up the playbook to retire on dividends for years (Two years ago, we literally wrote the book on the retirement strategy.)

So it was a hoot to see Barron’s run a cover story about retiring on dividends. But I have a bit of constructive criticism about the piece: the dividend stocks highlighted in the feature article had yields too low to actually retire on.

The magazine’s 10 buys included Coca-Cola (KO), International Business Machines (IBM) and Johnson & Johnson (JNJ) and had an average current yield of 4.1% between them (as of the time the piece was written).… Read more

Read More

It’s Never Been Easier to Retire on Dividends (Can Be Done on $600K)

Let me start with a special shout out to our dedicated readers at Barron’s. Here at Contrarian Outlook, we’ve been drawing up the playbook to retire on dividends for years (Two years ago, we literally wrote the book on the retirement strategy.)

So it was a hoot to see Barron’s run a cover story about retiring on dividends. But I have a bit of constructive criticism about the piece: the dividend stocks highlighted in the feature article had yields too low to actually retire on.

The magazine’s 10 buys included Coca-Cola (KO), International Business Machines (IBM) and Johnson & Johnson (JNJ) and had an average current yield of 4.1% between them (as of the time the piece was written).… Read more

Read More

The Ultimate Income Investment: 7% Dividends, 123% Profits Ahead

Most people don’t realize it, but there are 500 funds out there paying massive dividends: I’m talking rich 7% payouts on average.

That’s five times more than index funds pay! And many of these 500 criminally overlooked funds clobber their benchmarks, too.

I’m talking about closed-end funds (CEFs), which are run by real human beings, not algorithms. And despite what most advisors will tell you, the stock-pickers running CEFs beat the market on the regular.

To see what I mean, consider two CEFs: the  Duff & Phelps Utility & Infrastructure Fund (DPG), which holds utility stocks  like NextEra Energy (NEE) and Dominion Energy (D), and the Tekla Healthcare Opportunities Fund (THQ), holder of major drug firms like Johnson & Johnson (JNJ) and Abbott Laboratories (ABT).… Read more

Read More

This Gives You an “Automatic” 9.4% Return, in Cash, From Pfizer

There’s a way for us dividend investors to tap the news of a COVID-19 vaccine for huge payouts of 10% and up. And we’ll position our portfolios for serious price upside, too.

I know the vaccine news has a bit of a “horse is out of the barn” feel to it. After all, the market and shares of the vaccine’s producer, Pfizer (PFE), have already popped (though the rally has taken a bit of a breather lately). But you’re not too late. With the three investments I’ll show you below, you could grab healthcare dividends much bigger than the 3.9% Pfizer pays now.… Read more

Read More

Categories